Welcome to Idorsia

Daridorexant Phase 3
data published in
The Lancet Neurology

Idorsia receives Japanese
PMDA approval of
PIVLAZ (clazosentan sodium)
150 mg

Idorsia presents at the
40th J.P. Morgan
Healthcare Conference

Idorsia receives US FDA approval of QUVIVIQ (daridorexant)
25 and 50 mg for the treatment of adults with insomnia

Our key assets have
the potential to
transform treatment in
the target indications...

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s success depends on its people.

Idorsia's development compounds target a number of different diseases.

20 Jan 2022	Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg
20 Jan 2022	The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia
12 Jan 2022	Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day’ campaign inspiring Americans to understand their relationship with sleep

Event	When
Full-Year 2021 Financial Results reporting*	February 8, 2022
Annual General Meeting of Shareholders	April 14, 2022
First-Quarter 2022 Financial Results reporting*	April 26, 2022
Half-Year 2022 Financial Results reporting*	July 26, 2022

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 17:20:11 CET

22.04 CHF

+0.96 (+4.55 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland